Literature DB >> 10469135

The half-life of human procathepsin S.

K Nissler1, W Strubel, S Kreusch, W Rommerskirch, E Weber, B Wiederanders.   

Abstract

Two processes, synthesis and degradation, contribute to the intracellular concentration of a protein. As most malignant tumors or tumor cell lines show elevated levels of proteinases, we studied the half-life of a cysteine proteinase, procathepsin S, in order to determine whether tumor cells can regulate their cathepsin concentration via changing the degradation rate of the enzyme. The following procathepsin S species were examined: wild-type procathepsin S in macrophages, recombinant procathepsin S in human embryonic kidney cells (HEK 293 cells), recombinant nonglycosylated procathepsin S in HEK 293 cells, wild-type procathepsin S in the established nonsmall cell lung carcinoma cell line 97TM1. The half-lives of both wild-type procathepsins S expressed in macrophages and in HEK 293 cells were 1 h, whereas that of procathepsin S in the tumor cell line was 2 h. Nonglycosylated procathepsin S was not processed. The degradation of mature cathepsin S proceeded with a half-life of 16-18 h. All cell lines studied secreted substantial amounts of procathepsin S into the culture medium. No further maturation of secreted procathepsin S has been observed in the culture medium. We suggest a disturbed sorting mechanism in tumor cells.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10469135     DOI: 10.1046/j.1432-1327.1999.00547.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  7 in total

1.  Cathepsin S deficiency confers protection from neonatal hyperoxia-induced lung injury.

Authors:  Hiroshi Hirakawa; Richard A Pierce; Gulbin Bingol-Karakoc; Cagatay Karaaslan; Meiqian Weng; Guo-Ping Shi; Ali Saad; Ekkehard Weber; Thomas J Mariani; Barry Starcher; Steve D Shapiro; Sule Cataltepe
Journal:  Am J Respir Crit Care Med       Date:  2007-08-02       Impact factor: 21.405

2.  Manipulating substrate and pH in zymography protocols selectively distinguishes cathepsins K, L, S, and V activity in cells and tissues.

Authors:  Catera L Wilder; Keon-Young Park; Philip M Keegan; Manu O Platt
Journal:  Arch Biochem Biophys       Date:  2011-09-29       Impact factor: 4.013

3.  Cathepsin S cannibalism of cathepsin K as a mechanism to reduce type I collagen degradation.

Authors:  Zachary T Barry; Manu O Platt
Journal:  J Biol Chem       Date:  2012-06-22       Impact factor: 5.157

4.  The clinical significance of cathepsin S expression in human astrocytomas.

Authors:  Thomas Flannery; David Gibson; Menakshi Mirakhur; Stephen McQuaid; Caroline Greenan; Anne Trimble; Brian Walker; Derek McCormick; Patrick G Johnston
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

5.  Cathepsin V is involved in the degradation of invariant chain in human thymus and is overexpressed in myasthenia gravis.

Authors:  Eva Tolosa; Weijie Li; Yoshiyuki Yasuda; Wolfgang Wienhold; Lisa K Denzin; Alfred Lautwein; Christoph Driessen; Petra Schnorrer; Ekkehard Weber; Stefan Stevanovic; Raffael Kurek; Arthur Melms; Dieter Bromme
Journal:  J Clin Invest       Date:  2003-08       Impact factor: 14.808

6.  Hispolon suppresses metastasis via autophagic degradation of cathepsin S in cervical cancer cells.

Authors:  Min-Chieh Hsin; Yi-Hsien Hsieh; Po-Hui Wang; Jiunn-Liang Ko; I-Lun Hsin; Shun-Fa Yang
Journal:  Cell Death Dis       Date:  2017-10-05       Impact factor: 8.469

Review 7.  Cathepsin S: investigating an old player in lung disease pathogenesis, comorbidities, and potential therapeutics.

Authors:  Ryan Brown; Sridesh Nath; Alnardo Lora; Ghassan Samaha; Ziyad Elgamal; Ryan Kaiser; Clifford Taggart; Sinéad Weldon; Patrick Geraghty
Journal:  Respir Res       Date:  2020-05-12
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.